A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Pfizer

Status and phase: Withdrawn; Phase 2

Conditions: Breast Neoplasms

Treatments: Drug: PF-3512676; Drug: docetaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00471159

A8501007

Details and patient eligibility

About

To assess the efficacy and safety of PF-3512676 administered in combination with docetaxel for the treatment of patients with advanced breast cancer.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female patients with confirmed advanced breast cancer.
• Patients with HER-2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracycline-based chemotherapy regimen.
• Patients with adequate general well-being, kidney and liver function.

Exclusion criteria

• Patients that have any condition that could affect patients safety, interfere with trial results, or makes the patient inappropriate for inclusion into study.
• Patients who have had prior chemotherapy for advanced breast cancer.
• Patients of child-bearing potential who are unwilling to use contraception.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)